VERIFICATION OF REPEATABILITY, WITHIN LABORATORYPRECISION, AND TRUENESS OF PlGF AND sFlt-1 TESTS ON THE ROCHE COBAS E801 SYSTEM

Dung Lê Thị Mai, Phúc Phạm Nguyễn Hữu, Huân Phạm Nguyên, Huyền Hứa Thị Mỹ, An Phù Thị, Ngọc Lê Thị Mỹ, Ngân Nguyễn Thị Kim

Main Article Content

Abstract

Objective: To evaluate repeatability, within laboratoryprecision, and trueness through experimentation of PlGF and sFlt-1 on the Cobas e801 testing system by Roche using electrochemiluminescence technique at Hùng Vương Hospital in Ho Chi Minh City. Subjects and Methods: Two serum control samples, Precicontrol MultiMarker1 - Roche, were used as experimental materials to evaluate repeatability, within laboratory precision, and trueness of PLGF  and sFlt-1  on the Cobas e801 system according to the CLSI EP15A3 guidelines for the “5×5” testing procedure. Data were collected and analyzed using Excel software. ANOVA test  was employed to compare mean values, standard deviations, variances, coefficients of variation of the experiment, and the range of confirmed values ​​with the manufacturer's published specifications to evaluate the experimental results. Results: The results of the repeatability and within laboratory precision experiments indicated that the PlGF and sFlt-1 values for both serum control samples were less than 2.5%, while the manufacturer reported a PlGF range of approximately 7.86% to 14% and sFlt-1 around 17%. The mean value of PlGF was within the verification limits, and the bias deviation was not statistically significant. The mean value of sFlt-1 fell outside the verification interval; however, the bias percentages for the two serum control samples were 5.88% and 4.38%, both below the allowable limit (6.64%) according to Westgard's guidelines. Conclusion: The experimental of verification repeatability, within laboratoryprecision, and trueness  of PlGF and sFlt-1 tests on the Cobas e801 system by Roche Diagnostic meets the required technical specifications. 

Article Details

References

1. Falco, S.D. The Discovery of Placenta Growth Factor and Its Biological Activity. Experimental & Molecular Medicine. 2012;44(1):1. doi:10.3858/ emm.2012.44.1.025
2. Khalil, A., Maíz, N., Garcia-Mandujano, R., Penco, J.M.P., Nicolaides, K.H. Longitudinal Changes in Maternal Serum Placental Growth Factor and Soluble Fms‐like Tyrosine Kinase‐1 in Women at Increased Risk of Pre‐eclampsia. Ultrasound in Obstetrics and Gynecology. 2016;47(3):324-331. doi:10.1002/uog.15750
3. Levine, R.J., Maynard, S.E., Qian, C., et al. Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine. 2004; 350(7): 672-683. doi:10.1056/ nejmoa031884
4. Myatt, L., Clifton, R.G., Roberts, J.M., et al. First-Trimester Prediction of Preeclampsia in Nulliparous Women at Low Risk. Obstetrics and Gynecology. 2012;119(6): 1234-1242. doi:10. 1097/aog.0b013e3182571669
5. Torry, D.S., Ahn, H., Barnes, E.L., Torry, R.J. Placenta Growth Factor: Potential Role in Pregnancy. American Journal of Reproductive Immunology. 1999;41(1): 79-85. doi:10.1111/ j.1600-0897.1999.tb00078.x
6. Clinical and Laboratory Standards Institute (CLSI): EP15-A3, User Verification of Precision and Estimation of Bias; Approved Guideline, Third Edition, 2014.
7. Clinical and Laboratory Standards Institute (CLSI): EP21-A: Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures, 2nd Edition, 2016.
8. Webside: https://westgard.com/clia-a-quality/ quality-requirements/ biodatabase1.html.